Clinical Trials Logo

Clinical Trial Summary

This phase 2 study evaluates the sequential combination of decitabine then midostaurin for the treatment of newly-diagnosed acute myeloid leukemia (AML) in older patients.


Clinical Trial Description

Treatment with decitabine, a cytidine analog, then midostaurin, a multi-target protein kinase inhibitor (PKI), may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01846624
Study type Interventional
Source Stanford University
Contact
Status Terminated
Phase Phase 2
Start date June 2013
Completion date August 31, 2016